Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies

<b>Introduction:</b> The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receivi...

Full description

Bibliographic Details
Main Authors: Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Hussain Mohammad, Preethi Cherian, Irina Al-Khairi, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Mohamed Abu-Farha, Jehad Abubaker, Fahd Al-Mulla
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Vaccines
Subjects:
IBD
COVID-19
vaccine
immunogenicity
infliximab
adalimumab
Online Access:https://www.mdpi.com/2076-393X/9/12/1471

Internet

https://www.mdpi.com/2076-393X/9/12/1471

Similar Items